SynthesisInternational journal of colorectal disease2021

Concurrent use of statins and neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and meta-analysis.

What the trial testedas reported · 1,863 people · 2021

Range includes no effect

+3%−14% to +24%

Bigger than 1 in 10 for all-cause mortality

As reported

RR 1.03, 95% CI 0.86–1.24 · the paper's word: All-cause mortality

Range includes no effect

+4%−15% to +26%

Bigger than 1 in 10 for all-cause mortality

As reported

RR 1.04, 95% CI 0.85–1.26 · the paper's word: All-cause mortality

the abstract, start to end

… outcomes (5-year overall survival: RR 1.03, 95%CI 0.86-1.24, p = 0.75; 5-year disease-free survival: RR 1.04, 95%CI 0.85-1.26, p = 0.73).

← favours treatmentfavours comparator →

could be chance

All-cause mortality

RR 1.030.86–1.24

All-cause mortality

RR 1.040.85–1.26

StatinsAll-cause mortality

1 / 3